Fig. 5

ZCCHC4 hampers the pro-apoptotic function of AL133467.2 in OXA-treated HCC cells. a Flow cytometry analyzing OXA (62.5 µM, 36 h)-induced apoptosis of ZCCHC4- and lncRNA- co-silenced HepG2 cells (n = 4–7 per group). NC, non-specific siRNA control. b, c Flow cytometry analyzing OXA (62.5 µM, 36 h and 62.5 µM, 48 h for HepG2 cells and Hep3B cells, respectively) -induced apoptosis of ZCCHC4- and AL133467.2-co-silenced HepG2 cells (b) or Hep3B cells (c) (n = 4 for (b) and (c)). d, e Immunoblot analysis of OXA (62.5 µM, 16 h and 83.3 µM, 18 h for HepG2 cells and Hep3B cells respectively)-induced cleaved PARP and γH2AX levels in ZCCHC4- and AL133467.2-co-silenced-silenced HepG2 cells (d) and Hep3B cells (e). f Flow cytometry analyzing OXA (62.5 µM, 36 h)-induced apoptosis of NC- or ZCCHC4- silenced WT cells or AL133467.2 KO cells (n = 3 and n = 4 for WT and AL133467.2 KO group, respectively). WT wild-type. g, h Immunoblot analysis of OXA (62.5 µM, 16 h) -induced cleaved PARP and γH2AX levels in NC- or ZCCHC4- silenced AL133467.2 KO cells. Data are shown as mean ± s.e.m. a–c, f *P < 0.05; **P < 0.01; ns not significant (unpaired Student’s t test). d, e, g, h One representative experiment of three is shown